Insulin Resistance, Impaired Postprandial Lipid Metabolism and Abdominal Obesity
A Deadly Triad

Keith N. Frayn
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK

Key Words
Coronary heart disease · Postprandial lipaemia · Insulin resistance · Dyslipidaemia · Abdominal obesity

Abstract
Objective: To review three ‘emerging risk factors’ for coronary heart disease, the physiological and pathophysiological mechanisms involved, and their inter-relationships. Background: Classical risk factors for coronary heart disease cannot adequately explain the high incidence of this disease. Abdominal obesity and impaired postprandial lipid metabolism have long been recognised as associates of coronary heart disease but only relatively recently has their importance as risk markers been established. Insulin resistance is now often seen as a common theme underlying many factors predisposing to coronary heart disease (CHD). Mechanisms: The mechanisms by which each of these markers relates to coronary heart disease may have common aspects. Specifically, they are all associated with a characteristic dyslipidaemia involving elevation of plasma triacylglycerol concentrations, reduction of high-density lipoprotein cholesterol (HDL-cholesterol) and the presence of small, dense low-density lipoprotein particles that may carry particular risk of atherogenesis. Insulin resistance is also associated with hypertension and impairment of endothelial function, and with a procoagulant state. Treatment: No specific or separate pharmacological treatment of any of these conditions separately has been shown to reduce the risk of CHD although each can be manipulated. Lifestyle modification, with increased physical activity and dietary change, may offer the best hope of primary prevention but to achieve this, interventions at government level rather than advice from individual physicians would probably be required. Conclusions: Abdominal obesity, impaired postprandial lipid metabolism and insulin resistance are all inter-related risk markers for CHD. They seem to reflect lifestyle in the developed and developing worlds and perhaps modification of lifestyle holds the greatest hope for their amelioration in the future.

Introduction
It has become increasingly clear that classical risk factors (listed in table 1) cannot explain the large number of cases of coronary heart disease (CHD) seen in developed or developing countries. For example, the distribution of plasma cholesterol concentrations in those who developed
Table 1. Classical and emerging risk factors for coronary heart disease

<table>
<thead>
<tr>
<th>‘Classical’</th>
<th>‘Emerging’</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipids</td>
<td>Lipids</td>
</tr>
<tr>
<td>Elevated total cholesterol</td>
<td>Exaggerated postprandial lipaemia</td>
</tr>
<tr>
<td>Elevated LDL-cholesterol</td>
<td>Small, dense LDL particles</td>
</tr>
<tr>
<td>Low HDL-cholesterol</td>
<td>Lp(a)</td>
</tr>
<tr>
<td>Elevated fasting TG</td>
<td>Coagulation-related factors (including fibrinogen, PAI-1, fibrin D-dimers)</td>
</tr>
<tr>
<td>Smoking</td>
<td>Insulin resistance</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Endothelial dysfunction</td>
</tr>
<tr>
<td>Male gender</td>
<td>Markers of inflammation (including CRP)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Chronic infection</td>
</tr>
<tr>
<td>Age</td>
<td><em>(Helicobacter pylori, Chlamydia pneumoniae)</em></td>
</tr>
<tr>
<td>Family history</td>
<td>Elevated homocysteine concentration</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Abdominal obesity</td>
</tr>
<tr>
<td>Obesity</td>
<td></td>
</tr>
</tbody>
</table>

The table is not intended to be exhaustive and the distinction between ‘classical’ and ‘emerging’ risk factors is necessarily rather subjective.

Table 2. Characteristics of the insulin resistance syndrome

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose intolerance</td>
<td></td>
</tr>
<tr>
<td>Hyperinsulinaemia</td>
<td></td>
</tr>
<tr>
<td>(Moderately) elevated fasting TG concentration</td>
<td></td>
</tr>
<tr>
<td>Increased postprandial lipaemia</td>
<td></td>
</tr>
<tr>
<td>Reduced HDL-cholesterol concentration</td>
<td></td>
</tr>
<tr>
<td>Preponderance of small, dense LDL particles</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
</tr>
<tr>
<td>Impaired endothelial function</td>
<td></td>
</tr>
<tr>
<td>Procoagulant state</td>
<td></td>
</tr>
</tbody>
</table>

This table is based upon the original description by Reaven [70] but it has been expanded since by many authors [73, 81, 98]. Reproduced from Frayn [99].

CHD overlaps closely with the distribution in those who remained disease-free in several large prospective studies [1, 2]. Therefore, there is increasing interest in identification of additional, non-classical, risk markers. A large number of new, ‘emerging’ risk markers has now been identified (table 1). In this review, only three of these will be discussed, namely impaired postprandial lipid metabolism (exaggerated postprandial lipaemia), upper body fat distribution (or abdominal obesity) and insulin resistance. These three are not independent, and insulin resistance may well be a common underlying basis not just of the other two markers described here, but also of others listed in table 2.

Impaired Postprandial Lipaemia

History of Recognition as a Risk Marker for CHD

The classical lipid risk factors for CHD (table 1) are based on measurements made in the fasting state. Elevated fasting low-density lipoprotein-cholesterol (LDL-cholesterol) concentrations and low HDL-cholesterol concentrations are well-recognised markers of increased CHD risk. Fasting plasma triglyceride (TG) concentrations are a risk marker for CHD [3], although in many studies it is described as only a relatively weak marker because of a strong inverse relationship between TG and HDL-cholesterol concentrations. HDL-cholesterol con-
centrations are more stable from day to day in any one individual, and because of this they tend to ‘win’ statistically when both HDL-cholesterol and TG concentrations are entered into multivariate analyses [3]. Recently, the nature of the LDL particles has been recognised as important: people who have a predominance of small, dense (lipid-depleted) LDL particles are at increased risk of CHD compared to those with larger, more lipid-rich LDL particles [4, 5]. Each particle of LDL carries one molecule of the large apolipoprotein B100 (apoB100), so that plasma apoB100 concentrations are an indicator of the number of LDL particles. Plasma apoB100 especially in conjunction with LDL particle size and fasting insulin has been shown to be a strong indicator of CHD risk (see below) [6].

It has long been suggested, however, that events occurring in the period following a meal (the postprandial period) may be of particular significance for the development of atherosclerosis. Moreton [7] in 1947 showed ‘sustained hyperlipaemia’, assessed from the turbidity of plasma following an oral fat load, in subjects with atherosclerosis, and concluded that ‘the cumulative effect of many fatty meals over a lifetime . . . may be the underlying cause of the intimal lipid deposition in human atherosclerosis’. Becker et al. [8] in 1949 showed a prolonged and exaggerated appearance of chylomicrons (carrying dietary fat) in the circulation following an oral fat load, in older compared to younger subjects; they concluded that the vascular wall in older people would be almost continually exposed to dietary fat, and that ‘the condition leading to that degenerative disease [atherosclerosis] has been found’. More than 20 years ago Zilversmit [9] proposed that atherogenesis was a postprandial phenomenon. By this he implied that remnants of lipoprotein particles involved in the response to a meal might have atherogenic effects on the vasculature.

**Physiological Mechanisms Underlying Postprandial Lipid Metabolism**

These early studies focussed attention on the events that occur in the postprandial period. When a healthy person eats a meal that contains fat, there is a relatively slow rise in plasma TG concentration (compared with the rise in glucose concentration), peaking typically at 3–5 h following the meal. Plasma TG concentrations then decline and return towards baseline. The response to eating a fatty meal may be defined in terms of the rise in plasma TG concentration, or ‘postprandial lipaemia’. This is measured as the area under the TG-time curve (usually above the baseline level), or the TG concentration at later time points. Several cross-sectional or case-control studies show that CHD is associated with increased postprandial lipaemia [10–14]. The link between impaired postprandial lipid metabolism and atherosclerosis seems to involve prolonged residence of small remnant particles in the circulation [15, 16]. Therefore, it is important to understand the events that occur in the postprandial period, how they may influence CHD risk, and how they may be modified.

On a typical Western-style diet, most people eat around 100 g of fat each day, mostly in the form of triacylglycerol (TG), and 300 g carbohydrate. A typical meal might contain 30–40 g fat and 100 g carbohydrate. It is useful initially to consider glucose metabolism in the postprandial period, since this is well understood and widely accepted. The amount of free glucose in the body (vascular plus extravascular glucose space) is very small, typically 12 g. Therefore, ingestion of 100 g carbohydrate has the potential to cause a major disturbance in blood glucose concentration (an eightfold rise). This does not happen because co-ordinated mechanisms come into play to increase glucose disposal from the plasma and suppress the entry of endogenous glucose [17]. Insulin is a major determinant of these responses, and in insulin resistance or insulin deficiency (e.g. in diabetes mellitus) the postprandial excursion in glucose concentration is exaggerated.

Exactly the same arguments can be made for lipid metabolism. The amount of TG in the circulation is very small, typically 3 g (with a plasma TG concentration of 1 mmol/l). Therefore, when 30–40 g fat is ingested, there is the potential for a large excursion in plasma TG concentration. In fact in normal, healthy subjects eating such a meal (33 g fat, 96 g carbohydrate) the plasma TG concentration on average increases twofold at peak [18]; it does not increase tenfold. Therefore, we may suppose that co-ordinated mechanisms must come into play to minimise the excursion in plasma TG concentration. Again, also, insulin appears to play a major role. The major mechanisms that minimise excursions in plasma TG concentrations in the postprandial state, so far as they are understood, include: (a) up-regulation by insulin of lipoprotein lipase in adipose tissue; (b) suppression of the release of non-esterified fatty acids (NEFA) from adipose tissue, and (c) suppression by insulin of hepatic very-low-density lipoprotein (VLDL)-TG secretion (fig. 1).

When there is an impairment of postprandial lipid metabolism, it is reasonable to suppose that the normal co-ordinated mechanisms regulating lipid metabolism have become disturbed. A clear example is in insulin resistance (see below, under ‘Insulin Resistance’) when
Fig. 1. Normal coordination of postprandial lipid metabolism by insulin. Insulin, secreted in response to the carbohydrate and protein contents of a mixed meal, has powerful effects on lipid metabolism. These include activation of adipose tissue lipoprotein lipase (LPL), suppression of non-esterified fatty acid release from adipose tissue and (probably, although not convincingly shown in vivo) suppression of hepatic secretion of very-low-density lipoprotein (VLDL)-triacylglycerol. IDL = Intermediate-density lipoprotein; LDL = low-density lipoprotein.

Pathophysiology

The effects of delayed removal of TG-rich lipoproteins in the postprandial period may be widespread. The action of the cholesteryl ester transfer protein (CETP) is normally a beneficial part of the process of reverse cholesterol transport – transport of excess cholesterol to the liver for excretion. When there is an expanded pool of TG-rich lipoproteins, as in the case of increased postprandial lipaemia, then CETP will mediate the exchange of TG from these particles with cholesteryl ester from the cholesteryl-rich lipoproteins, LDL and HDL. The result is that the remnants formed from VLDL and chylomicron metabolism are enriched in cholesterol. It has been suggested that this makes these remnant particles more atherogenic. There is continuing debate about whether the chylomicron remnants themselves might be deposited in the arterial wall to begin the process of atherogenesis [20, 21]. Better established are the effects on LDL and HDL. Through the action of CETP, these particles have now become depleted of cholesteryl ester but enriched with TG. Their TG is a substrate for hydrolysis by the enzyme hepatic lipase. The result is LDL and HDL particles that have become depleted of lipid – so-called small, dense LDL particles, and a low HDL-cholesterol concentration (fig. 2). As noted earlier, these are aspects of the atherogenic lipoprotein phenotype that is strongly predictive of CHD risk [22, 23].

As discussed in more detail later (under ‘Insulin Resistance’), plasma NEFA may play a role in the adverse effects of impaired postprandial lipid metabolism. Failure of insulin to suppress plasma NEFA concentration normally may result in a greater drive for hepatic VLDL-TG secretion. VLDL particles compete with chylomicrons for TG clearance by lipoprotein lipase in peripheral tissues [24], so this can accentuate lipaemia. In addition, NEFA increase the activity, and possibly the mass, of CETP in plasma [25, 26], and will therefore accentuate the dyslipidaemia resulting from increased postprandial lipaemia.

Modification of Postprandial Lipaemia

What treatments can improve postprandial lipid metabolism? The weight-reducing drug orlistat (Xenical, Roche) inhibits pancreatic lipase in the small intestine and therefore reduces absorption of dietary fat. Orlistat should therefore be the perfect drug to lower postprandial TG concentrations. In one study in which this was tested, however, it was not found to do so [27]. The fibrate hypo-
lipidaemic drugs have potent effects in reducing postprandial lipaemia [28]. The HMG-CoA reductase drugs ('statins') also have a significant effect, which is of the same order of magnitude as their effect on fasting TG concentrations [29].

Lifestyle modifications can certainly be of benefit. The best documented such change is physical activity. A well-trained athlete has extremely good lipid tolerance, although this capacity is lost rapidly when training is interrupted [30]. A single bout of physical activity will markedly improve postprandial lipid metabolism when tested the following day [31], although again this effect is lost within a few days [32, 33]. Regular physical activity, known in any case to reduce CHD risk [34], is therefore a means of beneficially modifying postprandial lipid metabolism, as well as reducing abdominal fat and improving sensitivity to insulin.

Abdominal Obesity and CHD Risk

History

It was noted by Jean Vague, working in Marseilles, France in the 1940s, that obesity could be sub-divided into upper-body, masculine-type obesity, which he called android obesity, and lower-body, female-type fat distribution that he called gynoid obesity [35]. Vague also noted that the former tended to be associated with diseases including diabetes, atherosclerosis and gout [36].

Many studies have confirmed the association between upper-body fat distribution and markers of CHD risk, including reduced HDL-cholesterol and moderately elevated TG concentrations: in fact, the typical dyslipidaemia associated with insulin resistance as reviewed in [37, 38]. Some prospective studies have shown a link between fat distribution (usually measured as the simple surrogate of waist to hip circumference ratio) and presence of CHD [39], or mortality from CHD [40–42]. The prevalence of abdominal obesity may explain, at least in part, the high incidence of CHD in certain ethnic groups such as South Asians [43].

Physiological Mechanisms

What is the mechanism by which upper-body obesity leads to insulin resistance, dyslipidaemia and increased risk of CHD? This is usually ascribed to the characteristic metabolic features of upper-body (abdominal) adipose tissue compared with lower-body (gluteal and femoral). When adipocytes are isolated from these depots and studied in vitro, consistent differences are found. Gluteal/femoral adipocytes are characterised by relatively low rates of lipolysis, with a low sensitivity to stimulation by β-adrenergic agonists [44]. In contrast, the ability of insulin to suppress lipolysis in lower-body adipocytes is high [45]. These adipocytes from the lower body seem to be specialised in retaining fatty acids, and resistant to releasing them. Adipocytes from the upper body, in contrast, respond more readily to stimulation of lipolysis, and lipolysis when stimulated is less readily suppressed by insulin [44–46]. Intra-abdominal adipocytes (especially those from the omental and mesenteric depots) show a particularly high rate of lipolysis in vitro [45, 46]. This difference is particularly marked in males [47]. Upper-body adipocytes, then, in comparison with those of the lower body,
are more metabolically active, and tend to release fatty acids more readily. It is then assumed that a greater rate of delivery of non-esterified fatty acids (NEFA, also called free fatty acids, FFA) into the circulation, from those with upper-body obesity compared with those with lower-body fat accumulation, may account for many of the differences in CHD risk. The detrimental effects of elevated NEFA concentrations on CHD risk are discussed in more detail below (under ‘Insulin Resistance’).

This hypothesis also neatly fits with the commonly-observed relative protection of pre-menopausal women from CHD compared with men: in general, women tend to have more lower-body fat than men. In fact, it has been suggested that differences between men and women in (postprandial) lipid metabolism disappear when adjusted for body fat distribution [48].

Abdominal obesity involves both subcutaneous and intra-abdominal fat accumulation [49]. There has been much debate about whether the intra-abdominal (or visceral) fat depots (mainly omental, mesenteric and perirenal) play a special role in the increased risk of CHD. Evidence for this comes from many studies in which the different depots have been measured by computed tomography or magnetic resonance imaging [50, 51]. However, other studies suggest than the subcutaneous abdominal depots are more important [52], and yet further studies show both intra-abdominal and subcutaneous abdominal depots to relate to aspects of insulin resistance [53–55]. This is a difficult matter to decide, because the two (intra-abdominal and subcutaneous abdominal depots) are closely correlated as reviewed in [56]: it is unusual to find accumulation of subcutaneous fat without accompanying intra-abdominal fat, and vice versa. It should be noted in passing that studies such as these have also shown lower-body fat depots to be protective against CHD [55, 57].

The special role attributed by many to intra-abdominal depots may have a mechanistic basis. Most of the omental and mesenteric depots liberate their NEFA directly into the portal vein, and so they may have direct effects on liver metabolism (including stimulation of glucone production and of VLDL-TG secretion). This hypothesis for the link between abdominal fat deposition and CHD risk has been called the ‘portal theory’ [56, 58]. However, this theory is based almost entirely on studies conducted in vitro, and a critical review of the evidence [56] suggests that it is likely that the totality of abdominal adipose tissue, which is both subcutaneous and intra-abdominal, is responsible for the abnormalities, by secretion of NEFA at a higher rate than would be typical for lower-body adipose tissue.

### Possible Treatment

It is important to ask what can be done to reduce central obesity in order to reduce CHD risk. Weight loss by dieting leads to loss of abdominal (intra-abdominal and subcutaneous abdominal) fat [59–61]. The only specific treatment, other than surgery, that has consistently been shown to have a selective effect on reducing abdominal fat is physical exercise [60, 62, 63]. In assessing the risk to an individual patient, it is generally accepted that the waist-hip ratio is a relatively crude measure: in very obese people both waist and hip expand whilst the ratio may not change. The use of waist circumference has recently been shown to be a useful clinical assessment of CHD risk. It may be used as a ratio to height, to allow for variations in the latter [64], alone as an indicator of need for weight management [65], or with the plasma TG concentration [66]. The use of waist circumference ≥ 90 cm for men, together with a plasma TG concentration ≥ 2 mmol/l, has shown to be highly discriminatory for the development of CHD.

### Insulin Resistance as a Unifying Theme

#### Historical Basis of the Concept of Insulin Resistance

Insulin resistance is defined as a requirement for greater concentrations of insulin than normal to elicit a given metabolic response. The concept of sensitivity to insulin was first proposed by Himsworth [67]. He showed that when he injected insulin, together with glucose, into diabetic patients, some patients showed a fall in plasma glucose concentration while others did not. The ‘insulin-sensitive’ patients tended to be thin, with early onset of the disease (what we would now call type 1 diabetes), and the ‘insulin-insensitive’ patients tended to be overweight with later onset of the disease (type 2 diabetes). It was recognised in the 1960s that insulin resistance is also prominent in non-diabetic obese people [68, 69]. In 1988, Reaven [70] published his seminal paper in which he described insulin resistance as the central feature of a constellation of associated, adverse changes including an adverse lipoprotein profile (moderately elevated triacylglycerol, reduced HDL-cholesterol concentrations) and hypertension, and with increased risk of development of type 2 diabetes and CHD. He coined the term Syndrome X for this syndrome, and proposed that it was relatively common even amongst non-diabetic, non-obese subjects. It is certainly true that in large, cross-sectional studies, fasting insulin concentrations (a marker of insulin resistance) are associated with these features [71]. The term
‘insulin resistance syndrome’ or ‘metabolic syndrome’ is now more commonly used for this pattern of disease markers. The original list proposed by Reaven has since been expanded and it is now recognised that an important additional factor is a change in the nature of LDL particles, with a predominance of so-called small, dense LDL, although the LDL-cholesterol concentration is usually only slightly raised [72]. The syndrome is also associated with increased postprandial lipaemia [73] (as discussed above) and with a pro-coagulant state, indicated by increased circulating concentrations of the fibrinolytic inhibitor, plasminogen activator inhibitor-1 (PAI-1) [74]. Reaven’s suggestions were based mainly on detailed physiological studies. Since then some prospective studies have found that elevated fasting insulin concentrations (as noted above, a marker of insulin resistance) are associated with increased CHD risk [75–80].

**Links between Insulin Resistance and CHD**

What is the link between insulin resistance and CHD? It is usually assumed that increased CHD risk is mediated through the associates of insulin resistance listed in table 2. Evidence from prospective studies suggests that there may be a more direct role of insulin resistance, but it is not clear what this might be. Recently, evidence has accumulated suggesting a role for impairment of endothelial function in insulin resistance [81]. Impaired endothelial function is certainly associated with many traditional risk factors for CHD, including hypercholesterolaemia, hypertension, cigarette smoking, diabetes mellitus, and a high-fat diet [82]. Impaired endothelial function may promote the development of atherosclerosis through its effects on vascular regulation, platelet and monocyte adhesion, vascular smooth muscle cell growth, and coagulation [82].

What is the link between all these different facets of insulin resistance? The most plausible link involves disruption by insulin resistance of the co-ordination of lipid metabolism that occurs in the postprandial period. Insulin normally co-ordinates a number of events during this period and each of these steps can become ‘insulin resistant’ [19]. The overall effect is a prolongation of postprandial lipaemia, greater exchange of lipids mediated by the cholesteryl-ester transfer protein, loss of HDL-cholesterol and formation of atherogenic small, dense LDL particles [83, 84]. This was discussed in more detail above.

A further unifying factor in the diverse pattern of adverse changes associated with insulin resistance may be elevation of the plasma concentration of non-esterified fatty acids (NEFA), also called free fatty acids (FFA). When fat stored in adipose tissue is mobilized, for instance during starvation or during exercise, NEFA are released into the circulation and transported, bound to albumin, to tissues such as skeletal muscle and liver where they may be substrates for oxidation. In addition, in the liver, NEFA may be esterified to glycerol to make TG that is secreted in very-low-density lipoprotein (VLDL) particles. VLDL particles are the precursors of LDL. The release of NEFA from adipose tissue is suppressed by insulin. Therefore, in the period following a meal, when insulin levels are high, plasma NEFA concentrations are usually low thereby reducing competition with glucose for oxidation. It also removes the main substrate for VLDL-TG synthesis. There is consistent evidence that insulin resistance, in obesity or in diabetes, for instance, is associated with elevated NEFA concentrations, implying that the effect of insulin on NEFA release from adipose tissue also becomes ‘resistant’ [85–87]. In particular, resistance of NEFA concentrations to suppression by insulin seems to be associated with increased CHD risk [88, 89]. There are many reasons why elevated NEFA concentrations, especially in the postprandial period, might have this effect. These include adverse effects on endothelial function [90, 91] and potentiation of the activity of the cholesteryl ester transfer protein (CETP), which is responsible for the formation of small, dense LDL particles and for loss of HDL-cholesterol [25, 26].

**Possible Modification of Insulin Resistance**

In view of the strong evidence for insulin resistance as a risk marker for CHD, it is important to ask whether it can be modified. The new thiazolidinedione anti-diabetic drugs (troglitazone, rosiglitazone, pioglitazone) are marketed as insulin-sensitizers. There is as yet no prospective evidence as to whether they will reduce CHD incidence. Lifestyle modifications that favourably influence insulin resistance are weight loss and increased physical activity. Since both obesity [92] and a sedentary lifestyle [34, 93] are known to increase CHD risk, these changes may bring important benefits. Recently, evidence has accumulated that a diet in which polyunsaturated fatty acids, particularly those of the n–3 variety, replace saturated fatty acids can improve insulin sensitivity as reviewed in [94, 95]. A diet of low glycaemic index, rich in complex carbohydrates rather than simple sugars, has also been shown to improve sensitivity to insulin [96]. Therefore, a prudent diet and regular exercise may exert beneficial effects on insulin resistance, and hence on risk of type 2 diabetes and CHD.
Conclusion

Classical risk factors for CHD are insufficient to explain the high incidence of the disease. Amongst more recently identified risk markers are impaired postprandial lipid metabolism (in fact this was identified as early as 1947 but has only relatively recently received much attention), an upper-body fat distribution (also first recognised in 1947) and insulin resistance. In fact these three markers are all associated, making the determination of cause and effect difficult. The case being developed above is that impairment of postprandial lipid metabolism is the ‘final common pathway’ leading to CHD. However, this is certainly arguable. Insulin resistance is also associated with a pro-coagulant state and impairment of endothelial function, and plausible links exist between both these and hypertension, CHD and myocardial infarction. Kaplan has described as ‘the deadly quartet’ the combination of upper-body obesity, glucose intolerance, hypertriglyceridaemia, and hypertension [97]. It seems unlikely that we will ever fully disentangle cause and effect amongst these, but they certainly form a powerful constellation of risk markers. Although mortality from CHD can be reduced by lowering of cholesterol and TG concentrations with statins and fibrates, the most physiological means for reducing the impact of this deadly quartet is certainly a combination of increased physical activity and a prudent diet. However, the reduction in risk achievable by lifestyle modification in those with established CHD is probably small; but perhaps there is still hope for benefits in primary prevention of CHD. To achieve real benefits, however, will require more than advice from physicians: it will require changes in government policies to encourage physical activity and reduce reliance on the motor car.

References


64 Ashwell M, Lejeune S, McPherson K: Ratio of waist circumference to height may be better indicator of need for weight management. BMJ 1999;312:377.

